Evolution of the Average Target: Veradigm Inc.

Evolution of the Average Target - Veradigm Inc.

Evolution of the Target Price: Veradigm Inc.

Evolution of the Target Price - Veradigm Inc.

Changes in Analyst Recommendations: Veradigm Inc.

9c8867486f9000685bdf870281961.nHWAuN7_xsHr5j6lRTAgwZ6WsKX9iZ4VQEbIPzkxTY4.6TT07pORmfOylErWPUdFsazu89KJzfB9LDeuZWAFN_3YAuL9sKuekoSLXQ~686e5b25e55b4eb78071ec12fecbccad
19/24/19 Deutsche Bank Downgrades Veradigm to Hold From Buy, Adjusts Price Target to $10 From $15 MT
19/24/19 RBC Halves Price Target on Veradigm to $11 From $22, Keeps Outperform Rating MT
03/24/03 Barclays Starts Allscripts Healthcare Solutions With Equalweight Rating, $11 Price Target MT
11/23/11 Deutsche Bank Adjusts Veradigm Price Target to $15 From $18, Maintains Buy Rating MT
06/23/06 Argus Research Downgrades Allscripts Healthcare Solutions to Hold From Buy MT
30/23/30 Deutsche Bank Adjusts Allscripts Healthcare Solutions Price Target to $18 From $21, Maintains Buy Rating MT
12/23/12 Stephens Initiates Allscripts Healthcare Solutions at Equalweight With $13 Price Target MT
01/23/01 Piper Sandler Downgrades Veradigm to Neutral From Overweight, Adjusts Price Target to $18.50 From $17 MT
18/22/18 JPMorgan Adjusts Price Target on Allscripts Healthcare Solutions to $20 From $19, Maintains Underweight Rating MT
09/22/09 Goldman Sachs Upgrades Allscripts Healthcare Solutions to Buy From Neutral, Adjusts Price Target to $23 From $22 MT
07/22/07 Deutsche Bank Adjusts Allscripts Healthcare Solutions Price Target to $21 From $20, Maintains Buy Rating MT
06/22/06 Deutsche Bank Adjusts Price Target on Allscripts Healthcare Solutions to $20 From $26, Maintains Buy Rating MT
16/22/16 KeyBanc Initiates Coverage on Allscripts Healthcare Solutions With Sector Weight Rating MT
12/22/12 Goldman Sachs Starts Allscripts Healthcare Solutions at Neutral With $21 Price Target MT
10/22/10 Piper Sandler Adjusts Price Target on Allscripts Healthcare Solutions to $17 From $19, Maintains Neutral Rating MT
18/22/18 Piper Sandler Adjusts Price Target on Allscripts Healthcare Solutions to $22 From $19, Maintains Neutral Rating MT
04/22/04 Deutsche Bank Lifts Allscripts Healthcare Solutions to Buy From Hold, Price Target to $26 From $20 MT
03/22/03 SVB Leerink Adjusts Allscripts Healthcare Solutions' Price Target to $24 from $22, Keeps Outperform Rating MT
25/22/25 SVB Leerink Upgrades Allscripts Healthcare Solutions to Outperform from Market Perform, Adjusts Price Target to $22 from $19 MT
25/22/25 Piper Sandler Adjusts Price Target on Allscripts Healthcare Solutions to $19 From $17, Maintains Neutral Rating MT
23/21/23 Deutsche Bank Adjusts Allscripts Healthcare Solutions PT to $20 From $18, Maintains Hold Rating MT
08/21/08 Canaccord Genuity Adjusts Price Target on Allscripts Healthcare Solutions to $21 From $18, Keeps Buy Rating MT
06/21/06 Allscripts Healthcare : RBC Lifts Price Target on Allscripts Healthcare Solutions to $19 From $17, Maintains Outperform Rating MT
20/21/20 Allscripts Healthcare : Deutsche Bank Adjusts Price Target on Allscripts Healthcare Solutions to $17 From $15, Maintains Hold Rating MT
02/21/02 Allscripts Healthcare : Argus Downgrades Allscripts Healthcare Solutions to Hold From Buy MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - +63.27%
+8.72%
+12.67%
+8.17%
+26.06%
+8.7%
-7.39%
+12.54%
+3.85%
+2.26%
Average +13.88%
Weighted average by Cap. +9.38%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.950USD
Average target price
8.000USD
Spread / Average Target
+61.62%
High Price Target
8.000USD
Spread / Highest target
+61.62%
Low Price Target
8.000USD
Spread / Lowest Target
+61.62%

Analyst Consensus Detail

Analyst consensus - Veradigm Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Veradigm Inc.
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Veradigm Inc.
  1. Stock Market
  2. Stocks
  3. MDRX Stock
  4. Consensus Veradigm Inc.